Immune-based identification of cancer patients at high risk of progression

Publication date: April 2018
Source:Current Opinion in Immunology, Volume 51
Author(s): Yann-Alexandre Vano, Florent Petitprez, Nicolas A Giraldo, Wolf H Fridman, Catherine Sautès-Fridman
Tumors are highly heterogeneous structures where malignant cells interact with a large variety of cell populations, including a clinically-relevant immune component. We review and compare the most recent methods designed to analyze and quantify the composition of immune and stromal microenvironment of tumors and discuss their use in identification of patients for high risk of progression. If the impact of the various immune components on patient's relapse share common rules in most malignancies, clear cell renal cell tumors behave differently with regards to immunity. We focus on this specific pathology to show how the tumor interacts with the host's immune system and how this intricate relationship shapes the clinical outcome.



http://ift.tt/2IxX3C7